Bacillus Calmette-Guerin Substrain Tice Live Antigen: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Bacillus Calmette-Guerin Substrain Tice Live Antigen. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Dysuria | 401% |
| Urinary frequency | 272% |
| Flu-like syndrome | 224% |
| Hematuria | 175% |
| Fever | 134% |
| Malaise/fatigue | 50% |
| Cystitis | 40% |
| Urgency | 39% |
| Nocturia | 30% |
| Cramps/pain | 27% |
| Rigors | 22% |
| Nausea/vomiting | 20% |
| Flu-like symptoms | 0% |
| Hemorrhagic cystitis | 0% |
| Chills | 0% |
| Bladder cramps | 0% |
| Nausea | 0% |
| Incontinence | 0% |
| Myalgia/arthralgia | 0% |
| Diaphoresis | 0% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
TICE® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.